Previous 10 | Next 10 |
SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial...
2023-08-11 16:02:08 ET Telesis Bio, Inc. (TBIO) Q2 2023 Earnings Conference Call August 10, 2023 04:30 p.m. ET Company Participants Todd Nelson - Founder, Chief Executive Officer Eric Esser - President, Chief Operating Officer Jen Carroll - Vice President of Inve...
2023-08-11 13:18:11 ET BofA has lowered its rating of Telesis Bio ( NASDAQ: TBIO ) to sector weight from overweight, citing in part a slowdown in biopharma spending. "Facing a tepid biopharma spending environment, we see limited top-line visibility," the analysts wrote in ...
2023-08-11 09:58:47 ET Codex DNA press release ( NASDAQ: TBIO ): Q2 GAAP EPS of -$0.28 beats by $0.05 . Revenue of $8.65M (+51.8% Y/Y) beats by $1.25M . For further details see: Codex DNA GAAP EPS of -$0.28 beats by $0.05, revenue of $8.65M beats by $1.25M
SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023. “We achieved important milestones this quarter toward our path to profitabi...
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with ...
2023-07-07 17:04:10 ET Summary Investing Group leaders share lessons learned from their years of investing. Sector specific and general investing lessons are discussed. Participating contributors cover value, biotech, energy, commodities, and arbitrage. ~ Tim Murph...
2023-06-23 17:20:45 ET Summary Investing Groups leaders discuss one investing mistake they made and lessons learned from that mistake. Lessons learned from these mistakes include the importance of recognizing and adapting to changing market conditions, avoiding excessive leverage,...
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 20...
SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their automated workflow solutions for streamlining discovery workflows in antibody and therapeutics development ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the f...
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced that it ...
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA platform. Going forward, the company will in...